Consider this report in JAMA by Rita Rubin, senior writer for JAMA medical news and perspectives, for example.2 According to Rubin, the launch of “two highly efficacious” COVID-19 vaccines has “spurred debate about the ethics, let alone the feasibility, of continuing or launching blinded, placebo-controlled trials …”
Rubin recounts how Moderna representatives told a Food and Drug Administration advisory panel that rather than letting thousands of vaccine doses to go to waste, they planned to offer them to trial participants who had received placebo.
Pfizer representatives made a similar announcement to the advisory panel. According to a news analysis published in The BMJ,3 the FDA and U.S. Centers for Disease Control and Prevention are both onboard with this plan, as is the World Health Organization.4
In the JAMA report by Rubin, Moncref Slaoui, Ph.D., chief scientific adviser for Operation Warp Speed, is quoted saying he thinks “it’s very important that we unblind the trial at once and offer the placebo group vaccines” because trial participants “should be rewarded” for their participation.
All of these statements violate the very basics of what a safety trial needs, which is a control group against which you can compare the effects of the drug or vaccine in question over the long term. I find it inconceivable that unblinding is even a consideration at this point, seeing how the core studies have not even concluded yet. The only purpose of this unblinding is to conceal the fraud that these vaccines are safe.
None of the COVID-19 vaccines currently on the market are actually licensed. They only have emergency use authorization — which, incidentally, also forbids them from being mandated, although this is being widely and conveniently ignored — as trials are still ongoing.